University of Colorado and Osage University Partners both backed a round that took the immune regulation-focused university spinout's total funding to at least $106m.
Q32 Bio, a US-based immune regulation drug developer pursuing University of Colorado and Medical University of South Carolina research, closed a $60m series B round yesterday co-led by OrbiMed Advisors and Acorn Bioventures.
The round included University of Colorado, spinout-focused investment firm Osage University Partners and Sanofi Ventures, the strategic investment arm of pharmaceutical firm Sanofi, as well as healthcare provider Children’s Hospital Colorado’s Center for Innovation, Atlas Venture, Abingworth and undisclosed additional investors.
Q32 Bio is developing…
